Optimization of swirler type dry powder inhaler device design – Numerical investigation on the effect of dimple shape, inlet configuration and mouthpiece constriction

2021 ◽  
pp. 105893
Author(s):  
Yun Hwan Kim ◽  
Darson Dezheng Li ◽  
Guan Heng Yeoh ◽  
Ali Abbas
2012 ◽  
Vol 64 (9) ◽  
pp. 1303-1315 ◽  
Author(s):  
Christian Friebel ◽  
Hartwig Steckel ◽  
Bernd W. Müller

Author(s):  
Thomas Kopsch ◽  
Darragh Murnane ◽  
Digby Symons

The release of drug from dry powder inhalers is strongly dependent on the patient's inhalation profile. To maximise the effect of the treatment, it is necessary to optimise dry powder inhalers to achieve drug delivery that (A) is independent of the inhalation manoeuvre and (B) is targeted to the correct site in the lung. The purpose of this study is to develop a dry powder inhaler with an adaptive bypass element that achieves desired drug delivery behaviour. Computational and experimental methods are used. First, the effect of a generic variable bypass element on entrainment behaviour is modelled. This is done by modelling a dry powder inhaler as a network of flow. Second, the behaviour of a potential variable bypass element, a flap valve, is studied both computationally and experimentally. Third, the flow resistances are optimised to achieve consistent and desired entrainment behaviour for patients with very different inhalation manoeuvres. A simulated dry powder inhaler device design was found that achieves an approximately constant entrainment flow rate of 12 L/min when total flow rates larger than 20 L/min are applied. The developed dry powder inhaler is predicted to accurately deliver drug for patients with highly different inhalation manoeuvres.


2015 ◽  
Vol 138 (4) ◽  
Author(s):  
Martin Sommerfeld ◽  
Silvio Schmalfuß

The efficiency of dry powder inhalers (DPIs) for drug delivery is still very low and is therefore the objective of intensive research. Thus, numerical calculations (computational fluid dynamics (CFD)) using the Euler/Lagrange approach without coupling are being performed in order to analyze flow structure and carrier particle motion within a typical inhaler device. These computations are being performed for a steady-state situation with a flow rate of 100 l/min. Essential for the detachment of the very fine drug powder (i.e., between 1 and 5 μm) from the carrier particles are the fluid stresses experienced by such particles (i.e., relative velocity, turbulence, and fluid shear) as well as wall collisions, which are both evaluated in the present study. Since the carrier particles are rather large (i.e., normally 50–100 μm), first the importance of different relevant fluid forces, especially transverse lift forces, is investigated. Moreover, the significance of the parameters in the particle–wall collision model is highlighted and a statistical analysis of particle–wall collisions in an inhaler is conducted. The improved understanding of particle motion in the normally very complex flows of inhalers will be the basis for optimizing inhaler design.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1936
Author(s):  
Francesca Buttini ◽  
Eride Quarta ◽  
Chiara Allegrini ◽  
Federico Lavorini

Pulmonary drug delivery is currently the focus of research and development because of its potential to produce maximum therapeutic benefit to patients by directing the drug straight to the lung disease site. Among all the available delivery options, one popular, proven and convenient inhaler device is the capsule-based dry powder inhaler (cDPI) for the treatment of an increasingly diverse range of diseases. cDPIs use a hard capsule that contains a powder formulation which consists of a mixture of a micronized drug and a carrier usually the lactose, known for its good lung tolerance. The capsule is either inserted into the device during manufacturer or by the patient prior to use. After perforating, opening or cut the capsule in the device, patients take a deep and rapid breath to inhale the powder, using air as the vector of drug displacement. The system is simple, relatively cheap and characterized by a lower carbon footprint than that of pressurized metered dose inhalers. This article reviews cDPI technology, focusing particularly on the importance of capsule characteristics and their function as a drug reservoir in cDPIs.


2020 ◽  
Vol 68 (8) ◽  
pp. 726-736
Author(s):  
Ryosuke Mitani ◽  
Shuji Ohsaki ◽  
Hideya Nakamura ◽  
Satoru Watano

2014 ◽  
Vol 8 (1) ◽  
pp. 8-13 ◽  
Author(s):  
Mark R. Elkins ◽  
Sandra D. Anderson ◽  
Clare P. Perry ◽  
Evangelia Daviskas ◽  
Brett Charlton

Introduction: Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF) or non-CF bronchiectasis. Efficient drug administration via DPIs depends on the device resistance and adequate (≥45L/min) inspiratory flows and volumes generated by individuals. Drypowder mannitol is delivered using a RS01 breath-actuated device developed by Plastiape, for Pharmaxis. The study aim was to determine in vivo if non-CF bronchiectasis patients’ inspiratory flows and volumes are adequate to use the RS01 DPI device. Materials and Methodology: An open, non-interventional study; enrolled 17 subjects with non-CF bronchiectasis, 18 to 80 years, with baseline FEV1 ≥1.0L and ≥50‰ predicted. Inspiratory flows and volumes were measured when subjects inhaled in a controlled manner through the RS01 device in series with a spirometer. Results: The mean inspiratory volume (IV) of non-CF bronchiectasis subjects was 2.08 ± 0.5L and achieved a mean PIF of 78.6 ± 11.2L/min with the inhaler device. Conclusion: Use of the RS01 DPI device allowed adequate inspiratory flow and volume for dispersion of dry-powder mannitol in non-CF bronchiectasis patients.


Sign in / Sign up

Export Citation Format

Share Document